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Bringing together discussion of innate immunity, B cell and T cell responses, vaccine design and ef-
ficacy, and the genetics of HIV and AIDS resistance allows us to access the extraordinary complexity
of viral immunity and host responsiveness.The word immunity is derived from the
Latin immunis, meaning without tax.
The term refers to the tax-exempt sta-
tus given for a time to returned soldiers
in the Roman state. The tax that our im-
mune systems have evolved to deal
with is the tax of infection, of parasit-
ism by simpler life forms. With slow-
growing, complex organisms like the
vertebrates, our particular concern is
the excessive tax levied by pathogens
that replicate and (in some cases) mu-
tate with extraordinary rapidity.
As obligate intracellular pathogens,
the viruses (Knipe et al., 2006) are the
simplest and most intimate of the var-
ious life forms (bacteria, fungi, worms,
etc.) that are programmed to live in, or
on, us. Some viruses can survive for
time in the external environment if,
say, they are located in sloughed cells
protected by mucus (foot-and-mouth
disease virus is a case in point), though
all ultimately rely on strategies requir-
ing further infection and replication in
naive hosts that allow high levels of
virus production to facilitate transmis-
sion. In the case of measles virus or
poliovirus that means other humans,
but we are only incidental hosts for
the hantaviruses (Hantan and Korean
hemorrhagic fever viruses) that are
maintained in Apodemus species.
Other viruses (like dengue) replicate
in both mosquitoes and humans,
whereas the broadly related Japanese
encephalitis virus will multiply in pigs,
mosquitoes, and man.
Viruses that live only in a single spe-
cies can compromise their pathoge-
nicity so that their hosts remain avail-
able in sufficient numbers to ensure
transmission. The herpesviruses, for
example, establish initially as lytic in-
fections that are soon controlled bythe innate then adaptive host re-
sponses, then transit to a persistent
or latent form that allows the mainte-
nance of viral DNA throughout a normal
human life span. Such viruses transmit
via sporadic reactivation to lytic phase
as, for example, in the cold sores
caused by Herpes simplex virus, or
the oropharyngeal production of
Epstein-Barr virus (EBV). The immune
response then cuts in again to limit
the extent of damage.
Continuing analysis of these large,
complex, viruses shows how they
have evolved various molecular strate-
gies to subvert immune elimination
(Lilley and Ploegh, 2005), but not to
the extent that they compromise the
survival of immunocompetent hosts.
Given the long phylogenetic history of
such pathogens, it is also likely that
our immune systems have coevolved
with them. On the other hand, patho-
gens that infect us as incidental hosts,
like West Nile virus, which replicates in
birds and mosquitoes, are under no
selective pressure to keep even some
of us alive.
Four of the five reviews that follow
deal with the aspects of adaptive im-
munity, the extraordinarily specific re-
sponse mechanism that is thought to
have first emerged in the bony fishes
about 350 million years ago (Cooper
and Alder, 2006) and must presumably
have been further enhanced by the
transition to land and an air-breathing
lifestyle. Thomas Do¨rner and Andreas
Radbruch look at the secreted, circu-
lating, and locally produced immuno-
globulins (Igs) that have at least the po-
tential to neutralize virus at the point of
mucosal entry, the holy grail for vacci-
nologists. Their discussion of the bal-
ance between established memory,Immunity 27,circulating Ig, and recall responses
has particular relevance for immuniza-
tion strategies. Antibody-mediated
immunity can be extraordinarily long
lived, reflecting the persistence of
both B cell memory and plasma cells
located in the bone marrow (Crotty
et al., 2003).
Susan Kaech and John Wherry deal
mainly with the CD8+ T cells that con-
stitute the major mechanism for virus
clearance after primary challenge with,
particularly, the smaller viruses. Large,
complex viruses like the herpesviruses
are also controlled by effector CD4+
T cells, operating mainly via inter-
feron-g (IFN-g)-mediated mechanisms
(Doherty et al., 2001). The analysis of
CD8+ T cell responses has, of course,
surged ahead since the introduction
of the MHCI+peptide tetramer tech-
nology by John Altman, Mark Davis,
and colleagues some ten years back
(Altman et al., 1996).
For the first time, the tetramers
allowed the quantitative analysis of
virus-specific CD8+ T cell responses
while also providing a mechanism for
recovering single T lymphocytes di-
rectly ex vivo for immediate molecular
analysis with, for example, single-cell
polymerase chain reaction (PCR) ap-
proaches. As a consequence, starting
from the partially differentiated naive,
postthymic precursor, the virus-spe-
cific CD8+ T cell response provides
an extraordinarily accessible target
for the analysis of immune repertoire
selection (Turner et al., 2006) and the
progressive acquisition of diverse mo-
lecular expression profiles that char-
acterize fully functional effector cells
(Johnson et al., 2003; Peixoto et al.,
2007), TCM and TEM memory cells,
and so forth. Kaech and Wherry focusSeptember 2007 ª2007 Elsevier Inc. 363
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lymphocyte subsets and the factors
influencing the underlying cell-fate
decisions, introducing a burgeoning
area of molecular and cellular analysis.
As this research proceeds, it’s impor-
tant to bear in mind, of course, that
even for T cell clones expanded from
a single precursor, we are working
with populations rather than direct
mother-to-daughter lineages.
The past 10 to 15 years have also
seen enormous advances in our un-
derstanding of the evolutionarily an-
cient innate immune system that we
share with nonvertebrate life forms.
Andreas Pichlmair and Caetano Reis
e Sousa focus particularly on the cou-
pling of viral recognition and the induc-
tion of type 1 interferon (IFN-I) genes.
Those of us who work with the influ-
enza A viruses have long known about
the importance of IFN-I-mediated
early control from the work of Otto Hal-
ler and colleagues with the Mx genes
(Salomon et al., 2007; Tumpey et al.,
2007). Most of us are now also very
conscious (Kabelitz and Medzhitov,
2007) of the toll-like receptors (TLRs)
that were first discovered in Drosoph-
ila by the fly geneticists (Ip and Levine,
1994) We ‘‘adaptive immunologists,’’ if
that is a legitimate description, might,
though, be much less aware of the
role played by atypical nucleic acids
in different subcellular compartments,
a particular focus of this review.
The two remaining articles that were
commissioned for this issue of Immu-
nity deal principally with the limits of
host responsiveness when it comes
to dealing with a persistent pathogen,
the human immunodeficiency virus
(HIV), which jumped recently from
chimpanzees to become established
in us (Keele et al., 2006). Through the
course of evolutionary time we would,
as implied in the discussion by Steven
Deeks and Bruce Walker, select a
human population that lives happily
with HIV. Socially, of course, we could
never accept the massive dieback in
the human family that this would in-
volve. Even so, some of the most
promising avenues for developing
novel possibilities for HIV control lie in
determining how the inherent genetic
resistance mechanisms described by
Deeks and Walker work at the molecu-364 Immunity 27, September 2007 ª2007lar and cellular levels. As those of us
who are involved in the Centre for
HIV and AIDS Vaccine Immunology
(CHAVI), the National Institutes of
Health (NIH) vaccine grant adminis-
tered by Barton Haynes at Duke Uni-
versity, realize, we have to go back to
analyzing the basics of virus transmis-
sion, genetic resistance, and the earli-
est phases of both innate and adaptive
immune responsiveness if we are to
develop novel conceptual and techni-
cal strategies for defeating this virus.
The extraordinarily difficult and frus-
trating problem of making an HIV vac-
cine is discussed by Norman Letvin,
who also gives us a short history of vac-
cination going back to the preimmunol-
ogy era of Edward Jenner. It is salutary
for immunologists to reflect that, with
the exception of the very successful
human papilloma virus vaccine devel-
oped by the immunologist Ian Frazer
and colleagues (Liu et al., 1998), the
enormous intellectual advances that
we have made in understanding the
nature of specific host responsiveness
have so far had little impact on immuni-
zation. Of course, that might be in the
process of changing as we incorporate
new molecular strategies gained from
the analysis of the innate immunity
into product design, but we should be
Figure 1. Shaping the Antiviral Response
The themes that location, amount, and timing
are important in determining antiviral response
magnitude and quality are as true for the part
played within the cell by viral nucleic acids
that modulate type 1 interferon production
and innate immunity as they are for the nonself
proteins and MHC+peptide complexes that
stimulate B cells and T cells. Understanding and
exploiting the complex, interactive processes
that operate between and within the innate
and adaptive responses is a central challenge
for viral immunity and vaccine design.Elsevier Inc.modest when we recall that we still
have no effective vaccines to protect
children in the developing world
against infection with malaria species.
and Mycobacterium tuberculosis.
A particularly fascinating conse-
quence of bringing these varied dis-
cussions of innate and adaptive immu-
nity together is the insights that emerge
concerning the commonality of re-
sponse mechanisms and the nature
of self versus nonself discrimination,
an obsession for our field since the
time of Paul Ehrlich (Silverstein, 2005).
Amounts, whether they be foreign nu-
cleic acids, proteins, or peptides com-
plexed to MHC glycoproteins, are
important when it comes to triggering
responses within the infected cell or in
a responding lymph node. The same
point can be made concerning both
location and timing (Figure 1).
Immunity in all its aspects is an
evolved not a designer system that
has, as we are coming to realize, dis-
tinct limitations when it comes to
dealing with rapidly mutating viruses
and microorganisms that have well-
developed mechanisms for hiding in
various host ecological niches. Given
the assistance provided by vaccines,
antibiotics, and antivirals, our immune
responses function to protect a good
number of us through a normal human
lifespan. What would happen, though,
if we should suddenly find ourselves
exposed to a virus that is as difficult
to deal with as HIV but spreads readily
via a respiratory route? The recent
SARS experience was a wake-up
call, though it turned out that the
coronavirus in question could be han-
dled well by healthy, young immune
systems (Chen and Subbarao, 2007).
We can’t afford to let up. The chal-
lenge for us as immunologists is to un-
derstand how the various elements
work and fit together, and then to then
develop innovative solutions that do
better than nature. Reading the current
set of reviews together might trigger
some new insights into how to proceed
with the challenge of making more-
effective vaccines. Immunity ranks
with the most complex of complex sys-
tems, along with neurobiology and cli-
mate change. Bringing together a di-
versity of understanding allows us to
accessat least someof thatcomplexity.
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